Current and novel drug therapies for idiopathic pulmonary fibrosis

References

• Olson AL Swigris JJ Lezotte DC Norris JM Wilson CG Brown KK Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003 Am J Respir Crit Care Med 2007 176 277 284 17478620
   PubMed Web of Science ®Google Scholar
• Gribbin J Hubbard RB Le Jeune I Smith CJ West J Tata LJ Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK Thorax 2006 61 980 985 16844727
   PubMed Web of Science ®Google Scholar
• Navaratnam V Fleming KM West J The rising incidence of idiopathic pulmonary fibrosis in the UK Thorax 2011 66 462 467 21525528
   PubMed Web of Science ®Google Scholar
• Maher TM The diagnosis of idiopathic pulmonary fibrosis and its complications Expert Opin Med Diagn 2008 2 1317 1331
   PubMedGoogle Scholar
• Raghu G Brown KK Bradford WZ A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis N Engl J Med 2004 350 125 133 14711911
   PubMed Web of Science ®Google Scholar
• Noth I Anstrom KJ Calvert SB A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2012 186 88 95 22561965
   PubMed Web of Science ®Google Scholar
• Ziesche R Hofbauer E Wittmann K Petkov V Block LH A preliminary study of long term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis N Engl J Med 1999 341 1264 1269 10528036
   PubMed Web of Science ®Google Scholar
• King TEJr Brown KK Raghu G BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 184 92 99 21474646
   PubMed Web of Science ®Google Scholar
• Daniels CE Lasky JA Limper AH Mieras K Gabor E Schroeder DR Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 2010 181 604 610 20007927
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, Jun 2001 and by the ERS Executive Committee, Jun 2001 Am J Respir Crit Care Med 2002 165 277 304 11790668
   PubMedGoogle Scholar
• Raghu G Collard HR Egan JJ An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 2011 183 788 824 21471066
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network Raghu G Anstrom KJ Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis N Engl J Med 2012 366 1968 1977 22607134
   PubMed Web of Science ®Google Scholar
• Maher TM Pirfenidone in idiopathic pulmonary fibrosis Drugs Today (Barc) 2010 46 473 482 20683502
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G Hollinger MA Giri SN Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level Am J Physiol 1999 276 L311 L318 9950894
   PubMed Web of Science ®Google Scholar
• Iyer SN Gurujeyalakshmi G Giri SN Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J Pharmacol Exp Ther 1999 291 367 373 10490926
   PubMed Web of Science ®Google Scholar
• Iyer SN Gurujeyalakshmi G Giri SN Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J Pharmacol Exp Ther 1999 289 211 218 10087006
   PubMed Web of Science ®Google Scholar
• Oku H Shimizu T Kawabata T Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis Eur J Pharmacol 2008 590 400 408 18598692
   PubMed Web of Science ®Google Scholar
• Azuma A Nukiwa T Tsuboi E Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2005 171 1040 1047 15665326
   PubMed Web of Science ®Google Scholar
• Taniguchi H Ebina M Kondoh Y Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 2010 35 821 829 19996196
   PubMed Web of Science ®Google Scholar
• Noble PW Albera C Bradford WZ Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 2011 377 1760 1769 21571362
   PubMed Web of Science ®Google Scholar
• Spagnolo P Del Giovane C Luppi F Non-steroid agents for idiopathic pulmonary fibrosis Cochrane Database Syst Rev 2010 9 CD003134 20824834
   PubMed Web of Science ®Google Scholar
• Raghu G Johnson WC Lockhart D Mageto Y Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study Am J Respir Crit Care Med 1999 159 1061 1069 10194146
   PubMed Web of Science ®Google Scholar
• Hunninghake GW Antioxidant therapy for idiopathic pulmonary fibrosis N Engl J Med 2005 353 2285 2287 16306527
   PubMed Web of Science ®Google Scholar
• Cantin AM Hubbard RC Crystal RG Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis Am Rev Respir Dis 1989 139 370 372 2913886
   PubMed Web of Science ®Google Scholar
• Gillissen A Nowak D Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy Respir Med 1998 92 609 623 9659525
   PubMed Web of Science ®Google Scholar
• Das SK White AC Fanburg BL Modulation of transforming growth factor-beta 1 antiproliferative effects on endothelial cells by cysteine, cystine, and N-acetylcysteine J Clin Invest 1992 90 1649 1656 1430195
   PubMed Web of Science ®Google Scholar
• White AC Maloney EK Lee SL Lanzillo JJ Fanburg BL Reduction of endothelial cell related TGF beta activity by thiols Endothelium 1999 6 231 239 10365774
   PubMed Web of Science ®Google Scholar
• Zafarullah M Li WQ Sylvester J Ahmad M Molecular mechanisms of N-acetylcysteine actions Cell Mol Life Sci 2003 60 6 20 12613655
   PubMed Web of Science ®Google Scholar
• Meyer A Buhl R Magnussen H The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis Eur Respir J 1994 7 431 436 8013597
   PubMed Web of Science ®Google Scholar
• Behr J Maier K Degenkolb B Krombach F Vogelmeier C Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression Am J Respir Crit Care Med 1997 156 1897 1901 9412572
   PubMed Web of Science ®Google Scholar
• Demedts M Behr J Buhl R High-dose acetylcysteine in idiopathic pulmonary fibrosis N Engl J Med 2005 353 2229 2242 16306520
   PubMed Web of Science ®Google Scholar
• Trulock EP Christie JD Edwards LB Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report – 2007 J Heart Lung Transplant 2007 26 782 795 17692782
   PubMed Web of Science ®Google Scholar
• Orens JB Estenne M Arcasoy S International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 2006 25 745 755 16818116
   PubMed Web of Science ®Google Scholar
• Christie JD Edwards LB Kucheryavaya AY The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report – 2011 J Heart Lung Transplant 2011 30 1123 1132 21962019
   PubMed Web of Science ®Google Scholar
• Panos RJ Mortenson RL Niccoli SA King TEJr Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment Am J Med 1990 88 396 404 2183601
   PubMed Web of Science ®Google Scholar
• Walter N Collard HR King TEJr Current perspectives on the treatment of idiopathic pulmonary fibrosis Proc Am Thorac Soc 2006 3 330 338 16738197
   PubMedGoogle Scholar
• Collard HR Moore BB Flaherty KR Acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2007 176 636 643 17585107
   PubMed Web of Science ®Google Scholar
• Kubo H Nakayama K Yanai M Anticoagulant therapy for idiopathic pulmonary fibrosis Chest 2005 128 1475 1482 16162746
   PubMed Web of Science ®Google Scholar
• Song JW Hong SB Lim CM Koh Y Kim DS Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome Eur Respir J 2011 37 356 363 20595144
   PubMed Web of Science ®Google Scholar
• Churg A Müller NL Silva CI Wright JL Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias Am J Surg Pathol 2007 31 277 284 17255773
   PubMed Web of Science ®Google Scholar
• Collard HR Calfee CS Wolters PJ Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol 2010 299 L3 L7 20418386
   PubMed Web of Science ®Google Scholar
• Tobin RW Pope CE2nd Pellegrini CA Emond MJ Sillery J Raghu G Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 1998 158 1804 1808 9847271
   PubMed Web of Science ®Google Scholar
• Raghu G Freudenberger TD Yang S High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis Eur Respir J 2006 27 136 142 16387946
   PubMed Web of Science ®Google Scholar
• Amigoni M Bellani G Scanziani M Lung injury and recovery in a murine model of unilateral acid aspiration: functional, biochemical, and morphologic characterization Anesthesiology 2008 108 1037 1046 18497604
   PubMed Web of Science ®Google Scholar
• Moran TJ Experimental aspiration pneumonia: IV. Inflammatory and reparative changes produced by intratracheal injections of autologous gastric juice and hydrochloric acid Arch Pathol 1965 60 122 129
   Google Scholar
• Teabeaut JR2nd Aspiration of gastric contents; an experimental study Am J Pathol 1952 28 51 67 14885406
   PubMed Web of Science ®Google Scholar
• Greenfield LJ Singleton RP McCaffree DR Coalson JJ Pulmonary effects of experimental graded aspiration of hydrochloric acid Ann Surg 1969 170 74 86 5789532
   PubMed Web of Science ®Google Scholar
• Kwan M Xu YD Raghu G Khalil N Acid treatment of normal rat lungs releases transforming growth factor-beta1 (TGF-beta1) and increases connective tissue synthesis. Proceedings of the American Thoracic Society (PATS) Am J Respir Crit Care Med 2007 175 A967
   Google Scholar
• Perng DW Chang KT Su KC Exposure of airway epithelium to bile acids associated with gastroesophageal reflux symptoms: a relation to transforming growth factor-beta1 production and fibroblast proliferation Chest 2007 132 1548 1556 17908704
   PubMed Web of Science ®Google Scholar
• Tcherakian C Cottin V Brillet PY Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease Thorax 2011 66 226 231 20880868
   PubMed Web of Science ®Google Scholar
• Lee JS Ryu JH Elicker BM Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 184 1390 1394 21700909
   PubMed Web of Science ®Google Scholar
• Raghu G Yang ST Spada C Hayes J Pellegrini CA Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series Chest 2006 129 794 800 16537884
   PubMed Web of Science ®Google Scholar
• Linden PA Gilbert RJ Yeap BY Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation J Thorac Cardiovasc Surg 2006 131 438 446 16434276
   PubMed Web of Science ®Google Scholar
• Maher TM Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment Clin Chest Med 2012 33 69 83 22365247
   PubMed Web of Science ®Google Scholar
• Cox M Nelson DR Lehninger: Principles of Biochemistry 5th ed New York WH Freeman 2008
   Google Scholar
• Daniels CE Wilkes MC Edens M Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 2004 114 1308 1316 15520863
   PubMed Web of Science ®Google Scholar
• Aono Y Nishioka Y Inayama M Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice Am J Respir Crit Care Med 2005 171 1279 1285 15735062
   PubMed Web of Science ®Google Scholar
• Vuorinen K Gao F Oury TD Kinnula VL Myllärniemi M Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia Exp Lung Res 2007 33 357 373 17849262
   PubMed Web of Science ®Google Scholar
• Daniels CE Lasky JA Limper AH Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 2010 181 604 610 20007927
   PubMed Web of Science ®Google Scholar
• Allen JT Spiteri MA Growth factors in idiopathic pulmonary fibrosis: relative roles Respir Res 2002 3 13 11806848
   PubMed Web of Science ®Google Scholar
• Chaudhary NI Roth GJ Hilberg F Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur Respir J 2007 29 976 985 17301095
   PubMed Web of Science ®Google Scholar
• Richeldi L Costabel U Selman M Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 2011 365 1079 1087 21992121
   PubMed Web of Science ®Google Scholar
• Richter A Puddicombe SM Lordan JL The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma Am J Respir Cell Mol Biol 2001 25 385 391 11588018
   PubMed Web of Science ®Google Scholar
• Phipps S Ying S Wangoo A Ong YE Levi-Schaffer F Kay AB The relationship between allergen-induced tissue eosinophilia and markers of repair and remodelling in human atopic skin J Immunol 2002 169 4604 4612 12370399
   PubMed Web of Science ®Google Scholar
• Hancock A Armstrong L Gama R Millar A Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung Am J Respir Cell Mol Biol 1998 18 60 65 9448046
   PubMed Web of Science ®Google Scholar
• Zhu Z Homer RJ Wang Z Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production J Clin Invest 1999 103 779 788 10079098
   PubMed Web of Science ®Google Scholar
• Belperio JA Dy M Burdick MD Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis Am J Respir Cell Mol Biol 2002 27 419 427 12356575
   PubMed Web of Science ®Google Scholar
• Rose CEJr Sung SS Fu SM Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung Microcirculation 2003 10 273 288 12851645
   PubMed Web of Science ®Google Scholar
• Moore BB Kolodsick JE Thannickal VJ CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury Am J Pathol 2005 166 675 684 15743780
   PubMed Web of Science ®Google Scholar
• Baran CP Opalek JM McMaken S Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis Am J Respir Crit Care Med 2007 176 78 89 17431224
   PubMed Web of Science ®Google Scholar
• Moore BB Paine R3rd Christensen PJ Protection from pulmonary fibrosis in the absence of CCR2 signalling J Immunol 2001 167 4368 4377 11591761
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M McCullumsmith RE Charo IF Kunkel SL Phan SH CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis Cytokine 2003 24 266 276 14609568
   PubMed Web of Science ®Google Scholar
• Bartram U Speer CP The role of transforming growth factor beta in lung development and disease Chest 2004 125 754 765 14769761
   PubMed Web of Science ®Google Scholar
• Corrin B Butcher D McAnulty BJ Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders Histopathology 1994 24 145 150 8181807
   PubMed Web of Science ®Google Scholar
• Kapanci Y Desmouliere A Pache JC Redard M Gabbiani G Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha Am J Respir Crit Care Med 1995 152 2163 2169 8520791
   PubMed Web of Science ®Google Scholar
• Broekelmann TJ Limper AH Colby TV McDonald JA Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis Proc Natl Acad Sci U S A 1991 88 6642 6646 1862087
   PubMed Web of Science ®Google Scholar
• Blobe GC Schiemann WP Lodish HF Role of transforming growth factor beta in human disease N Engl J Med 2000 342 1350 1358 10793168
   PubMed Web of Science ®Google Scholar
• Postlethwaite AE Keski-Oja J Moses HL Kang AH Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta J Exp Med 1987 165 251 256 3491869
   PubMed Web of Science ®Google Scholar
• Desmoulière A Geinoz A Gabbiani F Gabbiani G Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts J Cell Biol 1993 122 103 111 8314838
   PubMed Web of Science ®Google Scholar
• Willis BC Liebler JM Luby-Phelps K Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis Am J Pathol 2005 166 1321 1332 15855634
   PubMed Web of Science ®Google Scholar
• Zhang HY Phan SH Inhibition of myofibroblast apoptosis by transforming growth factor beta(1) Am J Respir Cell Mol Biol 1999 21 658 665 10572062
   PubMed Web of Science ®Google Scholar
• Phan SH The myofibroblast in pulmonary fibrosis Chest 2002 122 286S 289S 12475801
   PubMed Web of Science ®Google Scholar
• Selman M Ruiz V Cabrera S TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000 279 L562 L574 10956632
   PubMed Web of Science ®Google Scholar
• García-Alvarez J Ramirez R Checa M Tissue inhibitor of metalloproteinase-3 is up-regulated by transforming growth factor-beta1 in vitro and expressed in fibroblastic foci in vivo in idiopathic pulmonary fibrosis Exp Lung Res 2006 32 201 214 16908447
   PubMed Web of Science ®Google Scholar
• Kulkarni AB Huh CG Becker D Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death Proc Natl Acad Sci U S A 1993 90 770 774 8421714
   PubMed Web of Science ®Google Scholar
• Annes JP Munger JS Rifkin DB Making sense of latent TGFbeta activation J Cell Sci 2003 116 217 224 12482908
   PubMed Web of Science ®Google Scholar
• Breuss JM Gallo J DeLisser HM Expression of the β6 subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling J Cell Sci 1995 108 2241 2251 7673344
   PubMed Web of Science ®Google Scholar
• Horan GS Wood S Ona V Partial inhibition of integrin alpha(v) beta6 prevents pulmonary fibrosis without exacerbating inflammation Am J Respir Crit Care Med 2008 177 56 65 17916809
   PubMed Web of Science ®Google Scholar
• Munger JS Huang X Kawakatsu H The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis Cell 1999 96 319 328 10025398
   PubMed Web of Science ®Google Scholar
• Puthawala K Hadjiangelis N Jacoby SC Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis Am J Respir Crit Care Med 2008 177 82 90 17916808
   PubMed Web of Science ®Google Scholar
• Bonniaud P Margetts PJ Ask K Flanders K Gauldie J Kolb M TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis J Immunol 2005 175 5390 5395 16210645
   PubMed Web of Science ®Google Scholar
• Higashiyama H Yoshimoto D Kaise T Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis Exp Mol Pathol 2007 83 39 46 17274978
   PubMed Web of Science ®Google Scholar
• Rucker RB Murray J Cross-linking amino acids in collagen and elastin Am J Clin Nutr 1978 31 1221 1236 27088
   PubMed Web of Science ®Google Scholar
• Yamauchi M Shiiba M Lysine hydroxylation and cross-linking of collagen Methods Mol Biol 2008 446 95 108 18373252
   PubMedGoogle Scholar
• Akiri G Sabo E Dafni H Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo Cancer Res 2003 63 1657 1666 12670920
   PubMed Web of Science ®Google Scholar
• Barry-Hamilton V Spangler R Marshall D Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment Nat Med 2010 16 1009 1017 20818376
   PubMed Web of Science ®Google Scholar
• Vadasz Z Kessler O Akiri G Abnormal deposition of collagen around hepatocytes in Wilson’s disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2 J Hepatol 2005 43 499 507 16023247
   PubMed Web of Science ®Google Scholar
• Saito H Papaconstantinou J Sato H Goldstein S Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence J Biol Chem 1997 272 8157 8160 9079631
   PubMed Web of Science ®Google Scholar
• Pascal T Debacq-Chainiaux F Chrétien A Comparison of replicative senescence and stress-induced premature senescence combining differential display and low-density DNA arrays FEBS Lett 2005 579 3651 3659 15963989
   PubMed Web of Science ®Google Scholar
• Lewis BP Burge CB Bartel DP Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell 2005 120 15 20 15652477
   PubMed Web of Science ®Google Scholar
• Lau NC Lim LP Weinstein EG Bartel DP An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans Science 2001 294 858 862 11679671
   PubMed Web of Science ®Google Scholar
• Galasso M Elena Sana M Volinia S Non-coding RNAs: a key to future personalized molecular therapy? Genome Med 2010 2 12 20236487
   PubMed Web of Science ®Google Scholar
• Grosshans H Filipowicz W Molecular biology: the expanding world of small RNAs Nature 2008 451 414 416 18216846
   PubMed Web of Science ®Google Scholar
• Tsai LM Yu D MicroRNAs in common diseases and potential therapeutic applications Clin Exp Pharmacol Physiol 2010 37 102 107 19671070
   PubMed Web of Science ®Google Scholar
• Pandit KV Milosevic J Kaminski N MicroRNAs in idiopathic pulmonary fibrosis Transl Res 2011 157 191 199 21420029
   PubMed Web of Science ®Google Scholar
• Fabbri M Garzon R Cimmino A MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B Proc Natl Acad Sci U S A 2007 104 15805 15810 17890317
   PubMed Web of Science ®Google Scholar
• Liu G Friggeri A Yang Y Milosevic J miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis J Exp Med 2010 207 1589 1597 20643828
   PubMed Web of Science ®Google Scholar
• Cushing L Kuang PP Qian J miR-29 is a major regulator of genes associated with pulmonary fibrosis Am J Respir Cell Mol Biol 2011 45 287 294 20971881
   PubMed Web of Science ®Google Scholar
• Oak SR Murray L Herath A A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis PLoS One 2011 6 e21253 21712985
   PubMed Web of Science ®Google Scholar
• Krützfeldt J Rajewsky N Braich R Silencing of microRNAs in vivo with ‘antagomirs’ Nature 2005 438 685 689 16258535
   PubMed Web of Science ®Google Scholar
• Mora AL Woods CR Garcia A Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice Am J Physiol Lung Cell Mol Physiol 2005 289 L711 L721 15734789
   PubMed Web of Science ®Google Scholar
• Mora AL Torres-González E Rojas M Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice Am J Respir Crit Care Med 2007 175 1139 1150 17363768
   PubMed Web of Science ®Google Scholar
• Méndez-Samperio P Hernandez M Ayala HE Induction of transforming growth factor-beta 1 production in human cells by herpes simplex virus. J Interferon Cytokine Res 2000 20 273 280
   Web of Science ®Google Scholar
• Malizia AP Keating DT Smith SM Walls D Doran PP Egan JJ Alveolar epithelial cell injury with Epstein-Barr virus upregulates TGF-beta1 expression Am J Physiol Lung Cell Mol Physiol 2008 295 L451 L460 18621908
   PubMed Web of Science ®Google Scholar
• Stoolman JS Vannella KM Coomes SM Latent infection by γherpesvirus stimulates profibrotic mediator release from multiple cell types Am J Physiol Lung Cell Mol Physiol 2011 300 L274 L285 21036917
   PubMed Web of Science ®Google Scholar
• Yonemaru M Kasuga I Kusumoto H Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis Eur Respir J 1997 10 2040 2045 9311499
   PubMed Web of Science ®Google Scholar
• Tang YW Johnson JE Browning PJ Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis J Clin Microbiol 2003 41 2633 2640 12791891
   PubMed Web of Science ®Google Scholar
• Magro CM Allen J Pope-Harman A The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis Am J Clin Pathol 2003 119 556 567 12710128
   PubMed Web of Science ®Google Scholar
• Vergnon JM Vincent M de Thé G Mornex JF Weynants P Brune J Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association? Lancet 1984 2 768 771 6148520
   PubMed Web of Science ®Google Scholar
• Egan JJ Stewart JP Hasleton PS Arrand JR Carroll KB Woodcock AA Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis Thorax 1995 50 1234 1239 8553293
   PubMed Web of Science ®Google Scholar
• Stewart JP Egan JJ Ross AJ The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 1999 159 1336 1341 10194186
   PubMed Web of Science ®Google Scholar
• Tsukamoto K Hayakawa H Sato A Chida K Nakamura H Miura K Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis Thorax 2000 55 958 961 11050267
   PubMed Web of Science ®Google Scholar
• Manika K Alexiou-Daniel S Papakosta D Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis Sarcoidosis Vasc Diffuse Lung Dis 2007 24 134 140 18496984
   PubMed Web of Science ®Google Scholar
• Vannella KM Luckhardt TR Wilke CA van Dyk LF Toews GB Moore BB Latent herpesvirus infection augments experimental pulmonary fibrosis Am J Respir Crit Care Med 2010 181 465 477 20185751
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG Young LS LMP1structure and signal transduction Semin Cancer Biol 2001 11 435 444 11669605
   PubMed Web of Science ®Google Scholar
• Sides MD Klingsberg RC Shan B The Epstein-Barr virus latent membrane protein 1 and transforming growth factor – β1 synergistically induce epithelial – mesenchymal transition in lung epithelial cells Am J Respir Cell Mol Biol 2011 44 852 862 20693406
   PubMed Web of Science ®Google Scholar
• Egan JJ Adamali HI Lok SS Stewart JP Woodcock AA Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study Pulm Med 2011 2011 240 805
   Google Scholar